RE:FDA offers clinical trial design on Accelerated ApprovalMarch 06, 2024 - " As a result of the Fast Track designation and the promising data reported to date, Oncolytics reports it is planning an adaptive phase 3 program and intends to manage it directly within its Clinical Group and a contract research organization (CRO) with the goal of enrolling the first patient in mid-2024."
https://www.benzinga.com/partner/biotech/24/03/37507096/oncolytics-biotech-nasdaq-oncy-tsx-onc-fights-cancer-with-pelareorep-which-has-received-fda-fast-